Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
2.000
+0.010 (0.50%)
Jan 14, 2025, 4:00 PM EST - Market closed
Compugen Revenue
Compugen had revenue of $17.13M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $59.85M, up 698.03% year-over-year. In the year 2023, Compugen had annual revenue of $33.46M with 346.12% growth.
Revenue (ttm)
$59.85M
Revenue Growth
+698.03%
P/S Ratio
2.97
Revenue / Employee
$880,176
Employees
68
Market Cap
179.07M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CGEN News
- 6 days ago - Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - PRNewsWire
- 6 weeks ago - Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies - PRNewsWire
- 2 months ago - Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Compugen Reports Third Quarter 2024 Results - PRNewsWire
- 2 months ago - Compugen to Participate in Stifel 2024 Healthcare Conference - PRNewsWire
- 2 months ago - Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 - PRNewsWire
- 2 months ago - Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - PRNewsWire
- 3 months ago - Compugen to Present New Clinical Data at SITC 2024 - PRNewsWire